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 1. Which of the following was found to be true regarding the 
different modalities of renal replacement therapy? 
(a)  Haemodialysis has a survival advantage in older patients 
compared to peritoneal dialysis patients. 
(b)  Peritoneal dialysis has a survival advantage in older patients 
compared to haemodialysis patients. 
(c)  Peritoneal dialysis patients were found to have worse 
treatment satisfaction scores compared to haemodialysis. 
(d)  The rate of cognitive decline was found to be faster in 
peritoneal dialysis compared with haemodialysis. 
(e)  There was no survival advantage identified between 
haemodialysis and peritoneal dialysis in older patients. 
 2. Which of the following is true regarding frail patients 
receiving renal replacement therapy? 
(a)  Frailty is restricted to older patients on dialysis. 
(b)  Targeting blood pressure of <140/90 mmHg has been 
shown to improve outcomes. 
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(c)  The prevalence of depression is similar to that of the 
general public. 
(d)  The symptom burden experienced is similar to that of 
patients with malignancy. 
(e)  There is no increased risk of fracture after a fall compared to 
the general public. 
 3. A 72-year-old man with heart failure with reduced 
ejection fraction was admitted with 2 weeks of 
increased orthopnoea, dyspnoea on exertion and ankle 
swelling. He was taking enalapril 5 mg twice daily 
(bd), bisoprolol 2.5 mg once daily (od), spironolactone 
50 mg od and furosemide 40 mg bd. Blood pressure was 
122/88 mmHg and heart rate was 66 beats per minute. 
His pre-admission baseline creatinine of 100 μmol/L 
was increased to 144 μmol/L. His potassium was 
4.8 mmol/L. 
 As well as changing oral furosemide to at least 80 mg bd 
intravenous , which is the correct change to his medication? 
(a)  Increase bisoprolol to 5 mg once daily. 
(b)  No change. 
(c)  Reduce enalapril to 2.5 mg twice daily. 
(d)  Reduce spironolactone to 12.5 mg once daily. 
(e)  Stop enalapril. 
 4. A 25-year-old man with no past medical history 
presented to emergency department with severe 
malaise. He was found to be anaemic with 
haemoglobin of 69 g/L (normal range 130–180 g/L). 
Blood film showed evidence of microangiopathic 
haemolysis and a thrombotic microangiopathy was 
suspected . 
 Which of the following would be more suggestive of a 
diagnosis of thrombotic thrombocytopenic  purpura  rather 
than complement-mediated atypical  haemolytic  uraemic 
 syndrome? 
(a)  ADAMTS13 activity >50%. 
(b)  Creatinine of 90 μmol/L (normal range 50–120 μmol/L). 
(c)  Family history of thrombotic microangiopathy. 
(d)  Platelet count of 90 × 10 9 /L (normal range 
150–400 × 10 9 /L). 
(e)  Shistocytes on blood film. 
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(c)  Mammalian target of rapamycin (mTOR) inhibitor. 
(d)  Prednisolone. 
(e)  Valganciclovir. 
 9. A patient with chronic kidney disease stage 3 (estimated 
glomerular filtration rate 49 mL/min/1.73 m 2 ) is admitted 
to hospital and is known to have heparin-induced 
thrombocytopenia. 
 Which form of heparin is safe to use if parenteral 
anticoagulation is required? 
(a)  Dalteparin. 
(b)  Enoxaparin. 
(c)  Fondaparinux. 
(d)  Tinzaparin. 
(e)  Unfractionated heparin. 
 10. A haemodialysis patient has suffered two unprovoked 
pulmonary emboli in the past year. It was decided that he 
requires long-term oral anticoagulation. 
 Which oral anticoagulant is currently licensed in the UK for 
use in this patient? 
(a)  Apixaban. 
(b)  Dabigatran. 
(c)  Edoxaban. 
(d)  Rivaroxaban. 
(e)  Warfarin. 
 5. A 27-year-old woman with a background of chronic 
kidney disease stage G4, A3 due to complement-
mediated atypical haemolytic uraemic syndrome, 
maintained in remission using eculizumab, presented to 
the emergency department with 4 hours of headache, 
vomiting and fever. 
 Which of the following is true regarding  eculizumab ? 
(a)  Contraindicated after renal transplant. 
(b)  Increased risk of infection with encapsulated organisms. 
(c)  Inhibits alternative pathway to prevent paroxysmal 
nocturnal haemoglobinuria. 
(d)  Mechanism of action is C1 inhibition. 
(e)  Migraine is a major side effect. 
 6. Which of these factors is a recognised  risk factor for cancer 
in a kidney transplant recipient? 
(a)  B cell depleting agents. 
(b)  Epstein–Barr virus. 
(c)  Herpes simplex virus. 
(d)  Obesity. 
(e)  Past alcohol history. 
 7. Which of the following recommendations is correct 
regarding screening for post-transplant malignancies? 
(a)  Two-yearly colonoscopy for those aged 60–74 years old to 
detect colorectal cancer. 
(b)  Three-yearly Papanicolaou smears in female recipients. 
(c)  Annual positron-emission tomography to screen for post-
transplant lymphoproliferative disorder. 
(d)  Annual ultrasound of native kidneys to detect renal cell 
cancer. 
(e)  No routine dermatology review is required. 
 8. Which of  these drugs is associated with an increased risk of 
malignancy in the post-transplant setting? 
(a)  Azathioprine. 
(b)  Cotrimoxazole. 
 CME Cardiovascular medicine SAQ 
 Answers to the CME SAQ published in  Clinical 
Medicine in January 2020 
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10
(b) (c) (a) (d) (d) (c) (b) (d) (b) (c)
CMJv20n2-Renal_Medicine_SAQs.indd   162 3/9/20   9:35 PM
